Insight Molecular Diagnostics Inc.
IMDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001642380
No open-market purchases or sales by Insight Molecular Diagnostics Inc. insiders were filed in the last 90 days; 40 institutions reported holding it in 13F filings for Q2 2026, worth $108.9M in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Insight Molecular Diagnostics Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 35 | 4 | 41 | +10 |
| Shares | 16.7M | 527.1K | 18.9M | +2.81M (+17.4%) |
| Value | $124.9M | $3.95M | $62.1M | −$58.8M (−48.6%) |
4 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Alyeska Investment Group, L.P. | 840,777 | $2.76M | 0.01% |
| Vanguard Capital Management LLC | 537,161 | $1.76M | 0.00% |
| Heights Capital Management, Inc | 392,545 | $1.29M | 0.36% |
| Vanguard Fiduciary Trust Co | 132,591 | $434.9K | 0.00% |
| Family Office Research LLC | 127,266 | $417.4K | 0.18% |
| Ghisallo Capital Management LLC | 70,695 | $231.9K | 0.01% |
| XTX Topco Ltd | 30,353 | $99.6K | 0.00% |
| Engineers Gate Manager LP | 18,253 | $59.9K | 0.00% |
| Flatrock Wealth Partners LLC | 13,044 | $42.8K | 0.02% |
| Point72 Asset Management, L.P. | 12,250 | $40.2K | 0.00% |
| Vanguard Global Advisers, LLC | 5,775 | $18.9K | 0.00% |
| Advisory Services Network, LLC | 3,100 | $10.2K | 0.00% |
| Golden State Equity Partners | 450 | $1.48K | 0.00% |
| Cassaday & Co Wealth Management LLC | 10 | $33 | 0.00% |
| Caitong International Asset Management Co., Ltd | 1 | $3 | 0.00% |
| Farther Finance Advisors, LLC | 1 | $3 | 0.00% |
| Federation des caisses Desjardins du Quebec | 1 | $3 | 0.00% |
Sold out (7)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Jane Street Group, LLC | 42,469 | $318.5K |
| Goldman Sachs Group Inc | 23,965 | $179.7K |
| Citadel Advisors LLC | 15,647 | $117.4K |
| Renaissance Technologies LLC | 13,400 | $100.5K |
| Hudson Bay Capital Management LP | 13,061 | $98.0K |
| Bank of America Corp | 335 | $2.51K |
| Tower Research Capital LLC (TRC) | 250 | $1.88K |
Not filed for Q1 2026 yet (4)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 526,675 | $3.95M |
| ORG Partners LLC | 450 | $3.38K |
| Global Retirement Partners, LLC | 1 | $8 |
| Motiv8 Investments LLC | 10 | $0 |